Annexon announces topline results from ARCHER Phase 2 trial of ANX007 for geographic atrophy
May 29th 2023Data supports ANX007 as the first complement therapy to preserve visual acuity, achieving statistically significant protection, but reduction in rate of geographic atrophy lesion growth did not reach statistical significance.
Oxurion reaches enrollment target in clinical trial for THR-149 in DME
May 26th 2023According to the company, THR-149 is currently being evaluated in the KALAHARI Phase 2, Part B clinical trial as a potential treatment for patients who respond suboptimally to anti-VEGF, the standard of care for treatment of DME.
AI used to advance drug delivery system for glaucoma and other chronic diseases
May 25th 2023The project, a collaboration with researchers from the University of Maryland, holds promise for advancing new and more tolerable drug treatments for common chronic blinding eye diseases, including glaucoma and macular degeneration.
Sight Sciences releases results of two-year multicenter ROMEO study
May 23rd 2023According to the company, study results show sustained reductions in both IOP and glaucoma medication use in mild-moderate primary open angle glaucoma patients treated with a procedure enabled with the OMNI Surgical System technology.